Is Dengvaxia recommended for immunocompromised patients?

Dengvaxia is a live-attenuated vaccine and is contraindicated in children with severe immunodeficiency or immunosuppression due to underlying disease or therapy, including children with symptomatic HIV infection or CD4+ T-lymphocyte count below 200 per cubic milliliter.

The ACIP recommendations state that Dengvaxia may be used with precaution in people with HIV infection who do not meet the criteria for contraindication, based on an assessment of the person’s risk of vaccination against the risk of dengue and its complications.